Acute Coronary Syndromes Fresh look at ACS in Europe, what is the real picture?

The face of ACS is changing. The ageing population and pressure of growing risk factors have made a significant impact on the management strategies in ACS. This report unveils the true picture through in-depth analysis of data on over 21,000 ACS patient records in the 5 major European pharmaceutical markets (5EU; France, Germany, Italy, Spain and the UK).

Scope

What are the current definitions, diagnostic methods and treatment approaches of the disease? To what extent are reperfusion therapies, such as PCI (percutaneous coronary intervention) and/or thrombolysis, used? What is the current role of pre-hospital thrombolysis and how is this likely to change in the future? What are the current hospital admission and logistics issues?

Highlights

Costs are no longer the restraining or dominant driver of a specific pharmacological strategy. Datamonitor's findings show that the routine use of troponins as cardiac markers has aided this development, with almost 90% of all ACS patients receiving tests for either troponin I or troponin T across the 5EU. A new definition for myocardial infarction has shifted a significant number of patients from unclear diagnosis of unstable angina to myocardial infarction moving from an essentially conservative and observational approach to an increase in more aggressive treatment strategies. Advances in novel imaging techniques provide opportunities to diagnose and treat the most complex ACS cases, however, inter-hospital logistics, necessary specialist training and cost constraints continue to prevent hospitals and clinicians from regular use of those diagnostic methods.

Reasons to Purchase

Understand current definitions, diagnostic methods and treatment approaches in ACS Quantify current dynamics of hospital logistics, conservative therapies and reperfusion therapies, such as PCI and thrombolysis Unveil the in-depth influencing factors leading to selection of specific pharmacological and interventional strategies.

26-Dec-07 PDF & DataPack Pages 164

Table of Contents
Price: $30,400.00 / GBP15,808.00